Laureate Pharma L.P. Announces the Election of Lawrence W. Chakrin to its Board of Directors

Princeton, NJ – January 7, 2003 – Laureate Pharma L.P. today announced the appointment of Lawrence W. Chakrin, Ph.D. as a new member of its Board of Directors.

Dr. Chakrin is Corporate Vice President of Science Applications International Corporation (SAIC), the largest employee-owned research and engineering firm in the United States, where he is responsible for corporate development of SAIC’s Biomedical Research Group.

Before joining SAIC, Dr. Chakrin was a consultant to companies in the pharmaceutical and biotechnology industries, as well as government agencies, including the National Institute of Health (NIH) and the Medical Research Council of Canada. Prior to that he was President and Chief Executive Officer of University City Science Center, President of Sterling Drug’s Research and Development Group, and with GlaxoSmithKline in a variety of increasingly responsible research and development positions over a 12-year period.

Dr. Chakrin holds a B.S. degree in Pharmacy from Long Island University, Brooklyn College of Pharmacy, a Ph.D. in Molecular Pharmacology from University of Minnesota Medical School, and a Postdoctoral Research Fellow at University of Cambridge, England. He also is the author of more than 100 scientific papers and holds several patents.

“It is my privilege to welcome Dr. Chakrin to our Board of Directors,” said Robert J. Broeze, Ph.D., President of Laureate Pharma L.P. “His knowledge of the biotechnology and pharmaceutical industry will be a tremendous asset to Laureate Pharma as we continue to develop and execute our plans for growth.”

About SAIC

SAIC is the nation’s largest employee-owned research and engineering company, providing information technology, systems integration and eSolutions to commercial and government customers. SAIC engineers and scientists work to solve complex technical problems in national and homeland security, energy, the environment, space, telecommunications, health care and transportation. With annual revenues of $6.1 billion, SAIC and its subsidiaries, including Telcordia Technologies, have more than 40,000 employees at offices in more than 150 cities worldwide. More information about SAIC can be found on the Internet at www.saic.com.

About Laureate Pharma

Laureate Pharma L.P. is a privately held contract manufacturing services company with headquarters in Princeton, NJ. The company is dedicated to supporting the development and commercialization of pharmaceutical products for small to large pharmaceutical and biopharmaceutical companies. Laureate Pharma’s biopharmaceutical division, located in Princeton, NJ, provides a wide range of product development services from process design and development to full-scale cGMP production, purification and aseptic filling, as well as corresponding analytical services and regulatory support. The division is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products utilizing hollow-fiber and stirred-tank bioreactors for production of biopharmaceutical products expressed by mammalian cells, and state-of-the-art semi-automated chromatography systems for purification of these protein products. Laureate Pharma’s extended release technologies division, located in Totowa, NJ, supplies sustained-release development, formulation and filling services through its cGMP manufacturing facility. For more information on Laureate Pharma, contact the company directly at 1.608.916.3570, by email at support@laureatepharma.com or visit www.laureatepharma.com.